Ann: Preliminary Final Report-MLA.AX, page-13

It would be remiss not to refine my previous post for the financials of the Tuta FirstFlow and MediFlush burettes based on further reading we’ve since done.

The WiseOwl research reports into Analytica, issued up to 2013, use a royalty figure of 15%. Their modelling of Analytica accounts show an incoming 15% and an outgoing 4% to the inventor (Angelo Maltabes). Analytica’s FY2016 report doesn’t contain any figures for outgoing royalties therefore I assume we need to use a net royalty figure for estimating sales of 11%.

Secondly, Analytica’s latest annual report contains royalty revenue of $10,679 and royalty cashflow of $7271 for FY2016. This is different to previous years where the two have always been the same.

Putting all this together means the increase in royalty revenue of $6,228 to $10,679 is actually 71%. Using a royalty figure of 11% gives estimated sales jumping from $57K in FY2015 to $97K in FY2016.

The royalty cashflow versus royalty revenue figure in Analytica’s reports is also intriguing. If we assume quarterly royalty payments, with the last physical payment delayed until after June 30, then this would mean the last quarter’s royalty payment was $3408. In relative terms this is quite high and suggests the reinvigoration programme by MLA is quietly happening behind the scenes.

Link to the research reports is here -
http://www.analyticamedical.com/Releases-ResearchNotes.html